US2010137228A2PendingUtilityA2

Drugs, foods or drinks with the use of algae-derived physiologically active substances

Assignee: TAKARA BIO INCPriority: Nov 11, 1997Filed: Aug 11, 2008Published: Jun 3, 2010
Est. expiryNov 11, 2017(expired)· nominal 20-yr term from priority
A61P 37/02A61P 43/00A61P 9/10A61P 9/00A61P 37/00A61P 39/06A61P 37/08A61P 9/02A61P 25/00A61P 25/22A61P 35/00A61P 27/16A61P 29/00A61P 3/10A61P 27/02A23L 33/105A61K 31/7048A61P 11/06A61P 1/10A61P 1/00A61P 1/04A61K 31/341A61P 13/12A61P 17/00A61P 19/02A01N 43/04A23B 2/779A23B 2/771A23B 2/733A61K 8/60
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1): foods, drinks, cosmetics, etc. containing as the active ingredient at least one member selected from the group consisting of the above-mentioned compound, its aldehyde, its hydrate and 2-O-methylated derivatives thereof and soluble sugar compounds containing the above compound. This compound also shows, for example, an apoptosis-inducing activity, a carcinostatic activity and inhibitory activities on the production of active oxygen, lipid peroxide radicals and NO, which makes it useful also as the active ingredient of antioxidants and preservatives.

Claims

exact text as granted — not AI-modified
1 . A method for treating a disease that requires induction of apoptosis for its treatment, a carcinomatous disease, a disease that requires protection against oxidation for its treatment, a disease that requires inhibition of active oxygen production for its treatment, a disease that requires inhibition of nitric monoxide production for its treatment, a disease that requires inhibition of lipid peroxide radical production for its treatment or a disease that requires immunoregulation for its treatment, the method comprising 
 administering a pharmaceutical composition which comprises as an active ingredient at least one member selected from the group consisting of:    (1) a compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by the formula (I):                          an aldehyde thereof, a hydrate thereof, and a 2-O-methylated derivative of said 3,6-anhydrogalactopyranose, said aldehyde or said hydrate; and    (2) a soluble saccharide containing the compound at its reducing end.    
   
   
       2 . A method according to  claim 1 , wherein the saccharide is a product produced by acid decomposition under acidic conditions below pH 7 and/or enzymatic digestion of a substance containing at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by said formula I, an aldehyde or a hydrate thereof, and a 2-O-methylated derivative of the 3,6-anhydrogalactopyranose, said aldehyde or said hydrate.  
   
   
       3 . A method according to  claim 2 , wherein the substance containing at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by formula I, an aldehyde and a hydrate thereof, and 2-0-methylated derivatives of the 3,6-anhydrogalactopyranose, the aldehyde and the hydrate is at least one substance selected from the group consisting of agar, agarose and carrageenan.  
   
   
       4 . A method according to  claim 1 , wherein the saccharide is at least one saccharide selected from the group consisting of agarobiose, agarotetraose, agarohexaose, agarooctaose, κ-carabiose, and β-D-galactopyranosyl-3,6-anhydro-2-O-methyl-L-galactose.

Join the waitlist — get patent alerts

Track US2010137228A2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.